Atara Biotherapeutics, Inc. (ATRA)

Oncology Corporate Profile

Stock Performance

15.3000
-0.1500

HQ Location

701 Gateway Blvd, Suite 200
South San Francisco, CA 94080

Company Description

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. Atara's lead programs target myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. In September 2014, Atara Biotherapeutics entered into an exclusive option agreement with MSK, under which it has the right to license (pursuant to a negotiated form of license agreement) the exclusive, worldwide rights to three clinical stage T-cell programs, including EBV-CTL, as well as other T-cell programs that are discovered or developed by MSK pursuant to sponsored research funded by the company.

Website: http://www.atarabio.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
WT1-CTLWT1 inhibitorMultiple MyelomaI
ATA129 (+ pembrolizumab)EBV-specific cytotoxic T lymphocytes (CTL)Nasopharyngeal cancer (NPC)IMerck
STM-434Activin A inhibitorOvarian cancerI
WT1-CTLWT1 inhibitorPlasma cell Leukemia (PCL)I
STM-434Activin A inhibitorVarious cancer typesI

View additional information on product candidates here »

Source: http://www.atarabio.com

Recent News Headlines

7/27/2017 12:17 pm

7/27/2017 12:17 pm

7/20/2017 06:17 am

7/19/2017 12:17 pm

6/15/2017 06:17 am

5/24/2017 06:17 am

5/24/2017 06:17 am

5/24/2017 06:17 am

5/10/2017 12:17 pm

5/10/2017 12:17 pm

5/10/2017 06:17 am

5/4/2017 12:17 pm

5/4/2017 12:17 pm

Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer

4/3/2017 12:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., April 03, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...

Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS)

3/17/2017 04:04 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 17, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that ...

Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights

3/9/2017 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 09, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...

Atara Bio to Present at the 35th Annual J.P. Morgan Healthcare Conference

1/4/2017 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Jan. 04, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...